Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...
Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...
On the left is integrase in its “intasome” structure of four identical four-part complexes (pink) that connect to create one 16-part complex that locks around viral DNA (blue). On the right is ...
In a randomized trial, ART intensification by doubling the dolutegravir dosage in people with HIV stably suppressed on ...
A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering ...
In a groundbreaking discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human ...
More than 40 years of AIDS research has led to significant advancements in treatment and prevention. Drugs to treat the infection continued to improve, as did patient outcomes. But now there's another ...
Living with HIV comes with unique health challenges, but advances in treatment have transformed it into a manageable chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results